Total Compensation FY2024
$20.3M
As reported in 2025 DEF 14A proxy filing with the SEC
Compensation Breakdown
Base Salary
$1.6M
8% of total
Stock Awards
$14.0M
69% of total
Bonus
$4.0M
20% of total
Other Compensation
$700,000
3% of total
About Albert Bourla
Albert Bourla has served as Pfizer's CEO since 2019, overseeing the development of the company's COVID-19 vaccine.
Data Source: Compensation figures are sourced from Pfizer Inc.'s DEF 14A proxy statement filed with the U.S. Securities and Exchange Commission (SEC) via EDGAR. Figures reflect total compensation for FY2024 as reported in the Summary Compensation Table.